A multi center, open label study to assess the inhibiton of Brain MAO-B by RG1577 after repeated dosing in Japanese patients with Alzheimers Disease using positron emission tomography (PET)

Trial Profile

A multi center, open label study to assess the inhibiton of Brain MAO-B by RG1577 after repeated dosing in Japanese patients with Alzheimers Disease using positron emission tomography (PET)

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Sembragiline (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 15 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top